Coagulopathy of Immunodermatologic Diseases The Molecular, Prognostic, and Therapeutic Implications of Crosstalk Between Coagulation, Fibrinolysis, and Inflammation in Immune-Mediated Skin Diseases

What this Trial Is About

Researchers are evaluating the coagulation and fibrinolysis profiles in people with autoimmune skin diseases, such as bullous pemphigoid, pemphigus vulgaris, mucous membrane pemphigoid, cutaneous lupus erythematosus, and dermatomyositis. The study compares blood samples from participants with active or poorly controlled immune-mediated skin diseases and those with mild or well-controlled conditions. A control group of general dermatology outpatients without immune-mediated skin diseases or certain skin cancers will also provide samples. This observational study aims to help guide future research on how these blood profiles relate to autoimmune skin conditions. Participants will have a one-time blood draw to measure various coagulation and inflammatory markers. Tests include standard coagulation assays such as activated partial thromboplastin time (aPTT) and international normalized ratio (INR), as well as viscoelastic coagulation profiles like rotational thromboelastometry and thromboelastography, including tPA-challenged versions. Blood samples from both groups will be analyzed and compared to understand differences in coagulation and fibrinolysis related to immune-mediated skin diseases. During the study, participants will provide detailed medical history and have their blood collected once for analysis. Researchers will measure primary outcomes including thromboelastography, tPA-challenged thromboelastography, aPTT, and INR over a two-year period to track coagulation function. This study includes adult participants aged 19 and older and involves healthy volunteers as controls. The total participation involves one visit for blood sample collection and history review.

Coagulopathy of Immunodermatologic Diseases